Compare OLED & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | ICUI |
|---|---|---|
| Founded | 1985 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1996 | 1995 |
| Metric | OLED | ICUI |
|---|---|---|
| Price | $80.92 | $160.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $125.00 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 639.4K | 242.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 9.25 | ★ 100.62 |
| EPS | 0.76 | ★ 1.20 |
| Revenue | $650,611,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $5.88 | N/A |
| Revenue Next Year | $10.36 | $4.46 |
| P/E Ratio | ★ $104.30 | $131.20 |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $77.15 | $107.02 |
| 52 Week High | $153.38 | $162.85 |
| Indicator | OLED | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 60.35 |
| Support Level | $77.33 | $139.88 |
| Resistance Level | $97.55 | $161.30 |
| Average True Range (ATR) | 2.24 | 4.67 |
| MACD | 0.36 | -0.55 |
| Stochastic Oscillator | 51.64 | 79.16 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.